DexCom, Inc. Stock London S.E.
Equities
0A4M
US2521311074
Medical Equipment, Supplies & Distribution
Market Closed -
Other stock markets
|
After market 12:20:19 | |||
126 USD | -2.68% | 115.9 | -8.02% |
05-30 | Redburn Atlantic Initiates DexCom With Neutral Rating, $130 Price Target | MT |
05-24 | Declaration of Voting Results by DexCom, Inc | CI |
Sales 2024 * | 4.33B 5.9B | Sales 2025 * | 5.15B 7.02B | Capitalization | 47.23B 64.36B |
---|---|---|---|---|---|
Net income 2024 * | 732M 998M | Net income 2025 * | 910M 1.24B | EV / Sales 2024 * | 11.2 x |
Net Debt 2024 * | 1.43B 1.96B | Net Debt 2025 * | 994M 1.35B | EV / Sales 2025 * | 9.36 x |
P/E ratio 2024 * |
65.7
x | P/E ratio 2025 * |
53.7
x | Employees | 9,550 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.62% |
Latest transcript on DexCom, Inc.
1 day | -8.01% | ||
1 week | -1.47% | ||
Current month | +7.43% | ||
1 month | +0.24% | ||
3 months | +3.27% | ||
6 months | +8.09% | ||
Current year | +1.18% |
Managers | Title | Age | Since |
---|---|---|---|
Kevin Sayer
CEO | Chief Executive Officer | 66 | 07-10-31 |
Jereme Sylvain
DFI | Director of Finance/CFO | 44 | 18-08-31 |
Chief Tech/Sci/R&D Officer | 47 | 22-09-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Nick Augustinos
BRD | Director/Board Member | 65 | 09-11-19 |
Mark Foletta
BRD | Director/Board Member | 63 | 14-11-18 |
Eric Topol
BRD | Director/Board Member | 69 | 09-07-08 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 117.3 | -0.65% | 6,684 |
24-05-30 | 118.1 | -7.54% | 1,949 |
24-05-29 | 127.7 | +0.47% | 1,264 |
24-05-28 | 127.1 | -0.63% | 1,929 |
Delayed Quote London S.E., May 13, 2024 at 10:39 am
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.37% | 178B | |
-0.90% | 107B | |
-2.14% | 67.04B | |
+11.62% | 44.62B | |
+9.25% | 42.5B | |
+14.39% | 29.99B | |
+15.97% | 25.22B | |
-6.80% | 24.14B | |
-6.23% | 23.69B |
- Stock Market
- Equities
- DXCM Stock
- 0A4M Stock